CYTOKINETICS INC 4

EVP & Chief Commercial Officer Andrew Callos exercised 14,000 stock options at $23.26 and sold 14,000 Cytokinetics (CYTK) common shares at $79.88 on 2026-07-30, leaving him with 58,555 shares held directly.

On July 30, 2026, Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, Inc., exercised 14,000 non-qualified stock options at $23.26 per share, acquiring 14,000 shares of common stock, and on the same day sold 14,000 shares of common stock at $79.88 per share in a transaction that appears structured to cover the exercise economically. The option exercise increased his directly held common stock to 72,555 shares immediately after the acquisition, while the subsequent sale reduced his direct holdings to 58,555 shares. The exercised options were originally granted on March 31, 2022 at a $23.26 strike price and vest over four years, and following the exercise, 10,000 options remain outstanding from this grant. Using the approximate market sale price of $79.88 per share as a proxy, his remaining 58,555 shares represent an estimated position of about $4.68 million in common stock after the reported transactions.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000086

Alert Tier

6